Anifrolumab PK study for Systemic Lupus Erythematosus (SLE)

Trial Identifier:	D3468C00002
Sponsor:	AstraZeneca
NCTID:	NCT05001698
Start Date:	July 2021
Primary Completion Date:	June 2022
Study Completion Date:	June 2022
Condition:	Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country	Location
CN	Nantong, CN, 226001
CN	Shanghai, CN, 200040
CN	Shanghai, CN, 200025
CN	Suzhou, CN, 215004

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.